Alnylam announces u.s. food and drug administration acceptance of supplemental new drug application for oxlumo® for the treatment of advanced primary hyperoxaluria type 1

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that the u.s. food and drug administration (fda) has accepted the company's supplemental new drug application (snda) for lumasiran, an investigational rnai therapeutic targeting hydroxyacid oxidase 1 (hao1) – the gene encoding glycolate oxidase (go) – for the reduction of plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1 (ph
ALNY Ratings Summary
ALNY Quant Ranking